...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Mutation research. Genetic toxicology testing >A NEW ANTHRACYCLINE WITH POTENT ANTILEUKEMIC ACTIVITY EXHIBITS REDUCED MUTAGENICITY
【24h】

A NEW ANTHRACYCLINE WITH POTENT ANTILEUKEMIC ACTIVITY EXHIBITS REDUCED MUTAGENICITY

机译：一种新的蒽环类药物具有强大的抗动能活性，降低了突变性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The mutagenicity of a new anthracycline (moflomycin) with potent antileukemic activity was studied by the Ames test in four strains of Salmonella typhimurium (TA97a, TA98, TA100 and TA102), and compared to the mutagenicity of doxorubicin, widely used as antineoplastic agent. Unlike doxorubicin, moflomycin displayed no mutagenic activity in strains TA98 and TA100. Low mutagenicity was only observed in TA102 strain acid was not enhanced after metabolic activation. This result indicates that moflomycin induce mutagenicity by reverting base-pair substitution. The structural changes in the sugar moiety may be involved in the reduced mutagenicity of moflomycin. The low mutagenicity of moflomycin shown in this study enhances the potential advantage of this new derivative which displays a high antileukemic activity.
机译：通过Ames试验在鼠伤寒沙门氏菌的四种菌株（TA97a，TA98，TA100和TA102）中研究了具有强抗白血病活性的新蒽环类药物（莫洛霉素）的致突变性，并与广泛用作抗肿瘤药的阿霉素的致突变性进行了比较。与阿霉素不同，莫来霉素在菌株TA98和TA100中没有诱变活性。仅在TA102菌株中观察到低致突变性，代谢激活后酸并未增强。该结果表明莫来霉素通过还原碱基对取代诱导诱变。糖部分的结构变化可能与莫来霉素的致突变性降低有关。这项研究中显示的美洛霉素的低致突变性增强了这种新衍生物的潜在优势，该新衍生物具有很高的抗白血病活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号